US Patent Office Plan To Expand Settlement Disclosure Requirements Welcomed By FTC

US Federal Trade Commission says the policy would enhance its ability to detect reverse payment settlements between pharmaceutical companies that raise antitrust concerns.

Efforts are Ongoing To Improve PTAB Processes. • Source: Shutterstock

The US Federal Trade Commission praised a proposal to close a patent settlement disclosure loophole from the Patent and Trademark Office, arguing it will ensure more of the agreements are reported.

Key Takeaways
  • The Federal Trade Commission supports a US Patent and Trademark Office proposal that would require patent settlement agreements be disclosed even if they are reached before a Patent Trial and Appeal Board proceeding.

  • The policy would extend the disclosure window, which now is required only after a proceeding is instituted

The policy is part of a broader

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Patents

More from Legal & IP